Impact of delisting high‐strength opioid formulations from a public drug benefit formulary on opioid utilization in Ontario, Canada

PURPOSE: High‐strength opioid formulations were delisted (removed) from Ontario's public drug formulary in January 2017, except for palliative patients. We evaluated the impact of this policy on opioid utilization and dosing. METHODS: We conducted a longitudinal study among patients receiving p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmacoepidemiol Drug Saf
Main Authors: Martins, Diana, Khuu, Wayne, Tadrous, Mina, Juurlink, David N., Mamdani, Muhammad M., Paterson, J. Michael, Gomes, Tara
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6518867/
https://ncbi.nlm.nih.gov/pubmed/30873707
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pds.4764
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados